Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NYSE:OGN NASDAQ:SANA NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.15-0.1%$25.31$19.05▼$32.56$3.81B0.722.67 million shs4.48 million shsOGNOrganon & Co.$13.35+0.2%$8.00$5.69▼$13.44$3.51B1.5719.29 million shs6.77 million shsSANASana Biotechnology$3.51+0.3%$3.36$1.60▼$6.55$947.67M2.173.61 million shs1.63 million shsVKTXViking Therapeutics$31.33-0.8%$33.55$22.96▼$43.15$3.64B0.722.38 million shs1.45 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-0.06%+8.39%+21.68%+27.45%+32.78%OGNOrganon & Co.0.00%+0.38%+92.99%+62.55%+52.62%SANASana Biotechnology+0.29%+7.34%+12.50%-10.69%+106.47%VKTXViking Therapeutics-0.79%+4.43%-10.36%+10.16%+13.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$31.15-0.1%$25.31$19.05▼$32.56$3.81B0.722.67 million shs4.48 million shsOGNOrganon & Co.$13.35+0.2%$8.00$5.69▼$13.44$3.51B1.5719.29 million shs6.77 million shsSANASana Biotechnology$3.51+0.3%$3.36$1.60▼$6.55$947.67M2.173.61 million shs1.63 million shsVKTXViking Therapeutics$31.33-0.8%$33.55$22.96▼$43.15$3.64B0.722.38 million shs1.45 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals-0.06%+8.39%+21.68%+27.45%+32.78%OGNOrganon & Co.0.00%+0.38%+92.99%+62.55%+52.62%SANASana Biotechnology+0.29%+7.34%+12.50%-10.69%+106.47%VKTXViking Therapeutics-0.79%+4.43%-10.36%+10.16%+13.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 2.88Moderate Buy$32.173.26% UpsideOGNOrganon & Co. 1.57Reduce$11.40-14.57% DownsideSANASana Biotechnology 2.63Moderate Buy$8.20133.62% UpsideVKTXViking Therapeutics 2.85Moderate Buy$95.50204.82% UpsideCurrent Analyst Ratings BreakdownLatest SANA, CPRX, OGN, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026CPRXCatalyst Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $31.505/7/2026CPRXCatalyst Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.005/7/2026CPRXCatalyst Pharmaceuticals Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2026CPRXCatalyst Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight5/1/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026VKTXViking Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.004/30/2026VKTXViking Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.004/30/2026VKTXViking Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$105.00 ➝ $100.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$588.99M6.47$2.92 per share10.66$7.76 per share4.01OGNOrganon & Co.$6.22B0.56$5.78 per share2.31$3.44 per share3.88SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$4.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.6918.4310.111.0136.39%36.47%31.85%5/11/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.353.881.243.99%99.95%6.22%N/ASANASana Biotechnology-$244.17M-$0.97N/AN/AN/AN/A-98.93%-41.01%5/14/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest SANA, CPRX, OGN, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SANASana Biotechnology-$0.15N/AN/AN/AN/AN/A5/11/2026Q1 2026CPRXCatalyst Pharmaceuticals$0.64N/AN/AN/A$149.52 millionN/A4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion4/29/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/A3/3/2026Q4 2025SANASana Biotechnology-$0.13-$0.16-$0.03-$0.21N/AN/A2/12/2026Q4 2025OGNOrganon & Co.$0.73$0.63-$0.10-$0.79$1.52 billion$1.51 billion2/11/2026Q4 2025VKTXViking Therapeutics-$0.89-$1.38-$0.49-$1.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/ASANASana BiotechnologyN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ALatest SANA, CPRX, OGN, and VKTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/20262/12/2026OGNOrganon & Co.quarterly$0.021.01%2/23/20262/23/20263/12/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.085.82OGNOrganon & Co.9.471.971.23SANASana BiotechnologyN/A1.891.89VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%OGNOrganon & Co.77.43%SANASana Biotechnology88.23%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%OGNOrganon & Co.1.62%SANASana Biotechnology25.40%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.35 million109.62 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableSANASana Biotechnology380269.99 million201.41 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableSANA, CPRX, OGN, and VKTX HeadlinesRecent News About These Companies75,475 Shares in Viking Therapeutics, Inc. $VKTX Bought by Channel Wealth LLCMay 9 at 4:15 AM | marketbeat.comVKTX stock slips overnight: Investors pin hopes on fresh weight-loss data as Pfizer joins Eli Lilly, Novo in GLP-1 warMay 6, 2026 | msn.comViking Therapeutics: Market Betting On Big Upside Through 2030May 5, 2026 | seekingalpha.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5, 2026 | finance.yahoo.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5, 2026 | prnewswire.comHere's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 MonthsMay 4, 2026 | fool.comViking Therapeutics (NASDAQ:VKTX) Trading 7.4% Higher - Still a Buy?May 4, 2026 | marketbeat.comViking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at BTIG ResearchMay 4, 2026 | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for VKTXMay 4, 2026 | americanbankingnews.comHC Wainwright Has Pessimistic Outlook of VKTX Q2 EarningsMay 4, 2026 | marketbeat.comWhy Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And LossMay 2, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN)May 1, 2026 | theglobeandmail.comPiper Sandler Sticks to Their Buy Rating for Viking Therapeutics (VKTX)May 1, 2026 | theglobeandmail.comViking Therapeutics faces timeline risk, but upside could be hugeMay 1, 2026 | msn.comViking Therapeutics Faces Timeline Risk—But Upside Could Be Huge...May 1, 2026 | marketbeat.comViking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comVKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal testsApril 30, 2026 | msn.comVKTX Q1 Earnings Miss on Higher Phase 3 Development CostsApril 30, 2026 | finance.yahoo.comVKTX Q1 Earnings Miss on Higher Phase 3 Development CostsApril 30, 2026 | zacks.comViking Therapeutics Earnings: Q3 Maintenance Study Data A Potential WildcardApril 30, 2026 | seekingalpha.comViking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid ...April 30, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeBy Chris Markoch | May 1, 2026Avis Short Squeeze Shocked the Market: Are These 3 Stocks Next?By Dan Schmidt | April 27, 2026SANA, CPRX, OGN, and VKTX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$31.15 -0.02 (-0.06%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$31.11 -0.04 (-0.12%) As of 05/8/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Organon & Co. NYSE:OGN$13.34 +0.03 (+0.19%) Closing price 05/8/2026 03:58 PM EasternExtended Trading$13.33 -0.02 (-0.13%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Sana Biotechnology NASDAQ:SANA$3.51 +0.01 (+0.29%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.52 +0.01 (+0.28%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Viking Therapeutics NASDAQ:VKTX$31.33 -0.25 (-0.79%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$31.37 +0.04 (+0.13%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
